(Circulation. 1995;92:1126-1132.)
© 1995 American Heart Association, Inc.
Articles |
From the Division of Cardiovascular Medicine, Stanford (Calif) University School of Medicine.
Correspondence to Alan C. Yeung, MD, Stanford University Medical Center, Division of Cardiovascular Medicine, 300 Pasteur Dr, Stanford, CA 94305.
| Abstract |
|---|
|
|
|---|
Methods and Results Thirty patients with baseline intravascular imaging within 3 weeks of cardiac transplantation who had at least one annual follow-up study were included in this study. Vessel luminal area (LA), total area (TA), intimal index (II=TA-LA/TA), mean intimal thickness (MIT), and Stanford classification were expressed for each image site and for each patient at each study. Progression of sites and of patients with and without PEDD on the baseline study was compared. Patients with PEDD (n=9) still had significantly more intimal disease than those without PEDD (n=21) at the first follow-up study (MIT=0.35±0.13 versus 0.13±0.11 mm; II=0.29±0.11 versus 0.11±0.1; class=3.7±0.5 versus 2.2±0.94; P<.001 for all comparisons). However, the increase in intimal thickness during the 1- year interval was not significantly different between the two groups. In 4 patients in whom both types of sites were present, no difference in progression was found. Data were similar for patients and sites studied over >1 year.
Conclusions PEDD does not accelerate the progression of TxCAD within the first few years after cardiac transplantation. The pathophysiology of TxCAD is most likely immune mediated and does not seem to be accelerated by native coronary artery disease.
Key Words: transplantation coronary disease ultrasonics
| Introduction |
|---|
|
|
|---|
Cardiac transplant recipients undergo a baseline coronary
angiogram before hospital discharge and return annually for
follow-up studies for surveillance for coronary
vasculopathy at Stanford University and many other institutions. Since
1990, we have included intracoronary ultrasound (ICUS) as
part of this surveillance. This technique is more sensitive than
angiography for observation of early allograft
vasculopathy,13 and it has suggested a prevalence of
approximately 20% for preexistent coronary artery lesions
among donors14 (Fig 1
). The objective of this
study was to
examine the effect of preexistent coronary artery lesions in
the donor heart on the subsequent progression of cardiac allograft
vasculopathy as assessed annually by intravascular ultrasound and
angiography.
|
| Methods |
|---|
|
|
|---|
The
Table
summarizes the clinical data of transplant
recipients and donors. The recipient population included 24 men and 6
women with a mean age of 52.2±9.4 years at the time of the baseline
study. Patients received a triple maintenance regimen for
immunosuppression combining cyclosporine, azathioprine, and
prednisone. Information regarding donor hearts was obtained through a
review of charts and data provided by our transplant registry. Donors
typically were young and died of unanticipated causes. The mean age of
the donor heart was 29.2±9.2 years (22 men, 8 women).
|
The study protocol was approved by the Committee for the Protection of Human Subjects in Research at Stanford University Medical Center, and written informed consent was obtained from all subjects before inclusion in this study.
Ultrasound Imaging Procedure and Analysis
Intravascular
ultrasound imaging was done with a 30-MHz
ultrasound transducer and rotating mirror system enclosed within an
acoustic housing at the tip of either a 5F or a 4.3F rapid exchange
catheter (Cardiovascular Imaging Systems Inc).
Intracoronary nitroglycerin (200 µg) or
sublingual nitroglycerin (0.4 mg) was given before
ultrasound imaging to prevent vasospasm and to minimize variations in
the vessel tone. After the patients were anticoagulated with heparin,
the imaging catheter was introduced through a guiding catheter over a
0.014-in coronary guide wire. The left main coronary
artery, proximal and middle portions of the left anterior descending
artery, or the circumflex artery was imaged. Coronary segments
<2 mm in diameter were avoided. During the baseline study, several
distinct arterial sites per patient were selected for
precise ultrasound measurements (Fig 1
). If intimal thickening
was
detected in the artery, the most severe thickening within that segment
was selected for measurement. Several other nondiseased segments that
were an equal distance apart also were recorded for measurements.
If no disease was detected in the artery, three to four segments that
were an equal distance apart were selected. Both ICUS and concomitant
angiography of these sites were obtained on sequential annual
studies.
The technique for replication of the imaging sites was reviewed in detail recently.15 In brief, the projection that best showed the artery to be studied with the least foreshortening and vessel overlap was chosen at the time of the first study. The height of the image intensifier and the C-arm angles were noted in the patient record so that this angulation could be duplicated in subsequent studies. A drawing and a video hard copy of the angiogram in this specific projection were obtained. The position of the radiopaque transducer in relation to the side branches visualized at the time of concomitant angiography was then filmed and marked in the drawing and hard copy for future reference. Imaging of the same sites on subsequent examinations was done according to the notes, drawing, and photos obtained in the initial examination and a review of the cineangiogram. Each coronary site was again imaged simultaneously with ultrasound and contrast angiography on each follow-up study. Accuracy of matching of the imaging sites was then determined off-line for each site with side-by-side comparison of the follow-up and baseline angiograms. One to four sites were studied per patient, but only sites that matched in subsequent evaluations were analyzed.
Ultrasound studies were recorded
on 0.5-in videotape and
analyzed off-line. Gain settings were adjusted for optimal
visualization of the vessel-lumen interface, and the images were
digitized. The frame with the largest lumen from the cardiac cycle
immediately before the contrast injection was selected for measurement.
Measurements included the luminal cross-sectional area (LA) and, if
intimal thickening was present, the total cross-sectional area
(TA) or area within the media layer (Fig 2
). The values
were entered into a customized database that calculated a mean intimal
thickness (MIT) from the difference between TA and LA. Also, an intimal
index, a measure of plaque area, was calculated (II=TA-LA/TA). We
previously showed good reproducibility and low interobserver and
intraobserver variabilities for the above-mentioned intravascular
parameters.16
|
To further categorize the degree of coronary
disease, all
segments studied were classified according to both the severity of
intimal thickening and the degree of circumferential involvement as
previously described13 (Fig 2
). The following
definitions
were applied: class 0 (none), no evidence of an intimal layer by
ultrasound and a homogeneous wall; class 1 (minimal),
intimal layer <300 µm thick involving <180° of the vessel
circumference; class 2 (mild), intimal layer <300 µm thick involving
>180° of the vessel circumference; class 3 (moderate), intimal layer
300 to 500 µm thick but involving <180° of the vessel
circumference or >500 µm thick at any point of the vessel cross
section; and class 4 (severe), intimal layer >500 µm thick involving
>180° of the vessel circumference or >1 mm at any point of the
vessel cross section.
For the purpose of this analysis and according to previous pathological studies, class 3 or 4 coronary intimal thickening was considered significant17 18 and was considered to represent preexistent donor disease if encountered in the baseline posttransplantation study.
Coronary Angiography
Coronary angiography was performed with
the
percutaneous femoral approach and standard angiographic
techniques. Multiple projections of both the right and left
coronary systems were obtained after
nitroglycerin premedication and duplicated in the
follow-up studies. Interpretation of serial cinefilms was based on
side-by-side comparisons with two projectors.
Coronary artery disease was classified as mild (<30% luminal
stenosis), moderate (31% to 69% luminal stenosis), or
severe (>70% luminal stenosis or diffuse pruning of distal
vessels).
Statistical Analysis
All data are expressed as mean±SD
for continuous variables
and as percentages for discrete variables. Comparisons between
groups were determined by the
2 test for
differences in proportions and by Student's t test or ANOVA
for differences in means. A two-sided value of P<.05
was considered statistically significant.
| Results |
|---|
|
|
|---|
Prevalence and Clinical Correlates of Donor Coronary
Artery Disease
Significant intimal thickening (class 3 or 4) by
intravascular
ultrasound was present in 19 of the 66 patients (28.8%)
constituting the full cohort of patients studied early after
transplantation. Of the 30 patients with serial studies, 9 (29%) had
at least one coronary site with class 3 or 4 intimal thickening
in the baseline study (29%) (see the Table
). These 30 patients
yielded
77 intracoronary sites (2.6 sites per patient) for image
analysis. Of these 77 sites, 15 (19.5%) had significant
disease by intravascular ultrasound.
At the baseline study, 28 of the
30 patients had completely
normal angiograms. Two patients (patients 19 and 24 in the
Table
) had
mild disease (<30% diameter stenosis), although the left
anterior descending artery was affected in only 1 patient. Both
patients had significant intimal thickening by intravascular
ultrasound.
Information regarding donor hearts was obtained by a review
of charts
and data provided by the Stanford transplant registry. Several
differences were noted between donors with and without coronary
artery disease detectable by intravascular ultrasound (the
Table
).
Allografts with coronary artery disease came from older donors.
The mean donor age of the nine allografts with preexistent disease was
37.4±6.2 versus 25.6±8 years for the 21 allografts without
baseline
disease (P<.001). All allografts with preexistent disease
came from patients >29 years of age (the Table
). Of the 9
allografts
with preexistent coronary disease, 8 came from male donors. The
prevalence of coronary disease in allografts from male and
female donors was 36% (8 of 22) and 12.5% (1 of 8), respectively
(P=NS).
There was a significant association between the presence of known risk factors for coronary disease in the donors and the existence of coronary lesions. Smoking, arterial hypertension, or family history of coronary heart disease was present in 7 of the 9 donors (77%) whose hearts had ultrasound evidence of preexistent disease. The process was present in only 4 of the 21 donors (19%) without risk factors (P<.01).
No differences were found in the duration of ischemia time during transplantation of allografts with and without preexistent coronary disease (160±21 versus 165±50 minutes, respectively, P=NS). The age of the recipients at the time of transplantation also was not different in the two groups (55.2±8 versus 50.9±9.8 years for recipients of allografts with and without preexistent coronary disease, respectively, P=NS).
Intravascular Ultrasound Measurements
Patients and
Sites With One Follow-up Evaluation
MIT and II were calculated per
patient, taking the average of the
measurements of all lesions in each patient. At baseline for the total
cohort of 30 patients, MIT was 0.10±0.12 mm, II was 0.09±0.10,
and
class was 1.6±1.1. Nine patients (29%) had donor disease and, by
definition, a higher MIT, II, and Stanford class than the 21 patients
without donor disease (Fig 3
). At the 1-year
follow-up study, the intimal thickening increased in both groups.
Patients with donor disease still had significantly more severe disease
than patients without donor disease as measured by MIT, II, and
Stanford class (all P<.001, Fig 3
). Although the
intima was
thicker at the follow-up study in patients with preexistent donor
disease, the increase in intimal thickness over this 1-year interval
was not significantly different between groups (Fig 4
).
|
|
The per-site analysis yielded similar findings.
Seventy-seven coronary sites were studied twice in
this group of 30 patients (2.6 sites per patient). Fifteen sites
(19.5%) were considered to have donor disease. At baseline
examination, by definition, they had a higher MIT (0.33±0.09 versus
0.04±0.06 mm), II (0.28±0.09 versus 0.04±0.06), and class
(3.1±0.3
versus 0.7±0.7) than the 62 sites without donor disease (all
P<.001). At the 1-year follow-up study, sites
with donor disease still had significantly more disease than sites
without donor disease. For sites with and without donor disease, MIT
was 0.38±0.20 versus 0.14±0.13 mm, II was 0.31±0.16
versus
0.12±0.11, and class was 3.3±0.96 versus 1.8±0.10 (all
P<.001), respectively. However, although ultrasound
parameters were still more severe at the follow-up
study in sites with preexistent donor disease, the increase (
) in
MIT and II was not significantly different between groups. For sites
with and without donor disease,
MIT was 0.05±0.18 versus
0.09±0.14
mm (P=NS),
II was 0.04±0.14 versus
0.08±0.12
(P=NS), and
class was 0.2±0.9 versus
1.0±1.2
(P<.05), respectively.
Patients and Sites With
Two or More Follow-up
Evaluations
Seventeen patients underwent three evaluations. At the
time of the
initial study, the average MIT was 0.11±0.14 mm, II was
0.10±0.12,
and class was 1.4±1.2. Over the 2-year period, there was a significant
increase in each ultrasound parameter of intimal thickening
(P<.01). On the second and third evaluations, the average
MIT increased to 0.18±0.18 and 0.24±0.2 mm, the II to
0.15±0.15 and
0.18±0.14, and class to 2.2±1.3 and 2.5±1.5,
respectively.
Of these 17 patients, 5 (29%) had donor disease.
Accordingly,
they had at baseline a higher MIT (0.31±0.06 versus 0.03±0.05
mm), II
(0.26±0.05 versus 0.03±0.04), and class (3±0 versus
0.7±0.7) than
the 12 patients without donor disease (all P<.001). At the
time of the third evaluation, 2 years after the baseline study,
patients with donor disease still had significantly more disease than
patients without donor disease (P=.05, Fig 5
).
Although the disease was more severe at the 2-year
follow-up study in patients with preexistent donor disease, the
interval increase in intimal thickness was not significantly different
between groups (Fig 4
).
|
Coronary artery disease
progression was also analyzed
on a per-site basis. Of the 36 sites studied three times in this
group of 17 patients (2.1 sites per patient), 8 (22%) were considered
to have donor disease. By definition, at baseline examination they had
a higher MIT (0.37±0.08 versus 0.05±0.07 mm), II
(0.31±0.08 versus
0.05±0.06), and class (3±0 versus 0.7±0.8) than the 28
sites without
donor disease (all P<.001). Two years later, sites with
donor disease still had significantly more disease than patients
without donor disease. For sites with and without donor disease, MIT
was 0.43±0.26 versus 0.21±0.22 mm, II was 0.31±0.15
versus
0.15±0.15, and class was 3.5±0.53 versus 2.0±1.4 (all
P<.05), respectively. Again, although the disease was more
severe at the end of follow-up study in sites with preexistent
donor disease, the increase in intimal thickness over this 2-year
period was not significantly different between groups. For sites with
and without donor disease,
MIT was 0.06±0.26 versus
0.16±0.23 mm,
II was 0.01±0.16 versus 0.11±0.16, and
class
0.5±0.53 versus
1.3±1.7 (P=NS), respectively.
Follow-up Angiography
At the time of the last intravascular
ultrasound and angiographic
evaluation, only 3 patients (patients 10, 19, and 24 in the
Table
) had
angiographic evidence of coronary artery disease. Two patients
(patients 19 and 24) already had evidence of mild coronary
disease when evaluated immediately after transplantation. In 2 patients
(patients 10 and 19), only mild lesions (<30%) were noted, and in 1
patient (patient 10), the lesions involved the left anterior descending
artery (the vessel evaluated by ultrasound). One patient (patient 24)
developed moderate disease in the right coronary artery, but
the left anterior descending artery had only mild disease by
angiographic assessment.
| Discussion |
|---|
|
|
|---|
The present study demonstrates that allografts from older donors and donors with recognized cardiac risk factors have evidence of early coronary atherosclerosis. The presence of the disease is not detectable by contrast angiography but is evident by the more sensitive intravascular ultrasound technique.13 This study demonstrates that patients receiving allografts with preexistent donor disease had more intimal thickening 1 and 2 years after the operation than patients who received grafts that were normal by ultrasound examination. This was by virtue of the preexistent disease. Preexistent donor coronary artery disease, however, is not a trigger for the accelerated development of coronary vasculopathy subsequently. The progression of intimal thickening at specific sites within the coronary arteries was not statistically significant between the two groups of patients. Four patients had sites with and sites without significant disease in the same vessel at the baseline study. No significant difference was noted for the change of intimal thickness over the 1-year period between sites with and without donor disease. Therefore, the data suggest that preexisting donor coronary disease does not provide the nidus for or potentiate transplant vasculopathy by any method of analysis.
Numerous advances in cardiac surgery, immunology, and antimicrobial therapy have permitted both long-term patient survival after cardiac transplantation and the widespread use of this procedure. Cardiac allograft vasculopathy is a unique form of coronary artery disease that is now the primary factor limiting long-term patient survival and the main reason for retransplantation.1 2 3 4 5 Our group and others reported that up to 50% of patients have evidence of vascular disease on coronary angiography by 5 years after transplantation.6 20 21 Importantly, the presence of angiographically detectable disease is associated with both graft failure and poor prognosis.20 22 23 Little is known about the etiology of transplant coronary disease. It is believed to be an immune-mediated process primarily because the disease is limited to the vascular bed of the allograft and the vessels are diffusely affected.20 24 25 26 However, clinical studies assessing the relation of cellular rejection and transplant coronary disease yielded conflicting, usually negative, results.2 6 7 20 27 28 29 30 31 32 Moreover, different immunosuppressive protocols were shown not to decrease the incidence or severity of transplant coronary artery disease.20 21 30 Some conventional risk factors for native coronary artery disease also were associated with the development of allograft vasculopathy. In particular, hyperlipidemia, obesity, and older donor age have been related to transplant coronary artery disease.6 7 8 9 10 11 18
Previous studies demonstrated intravascular ultrasound is more sensitive than contrast angiography for diagnosis of the early stages of coronary disease.13 14 Although coronary angiograms may be normal immediately after transplantation,20 22 our study has demonstrated that transplanted preexistent coronary artery disease is common. The incidence of preexisting transplant coronary diseases varies from 30% to 50%,33 depending on the ultrasound criteria. These baseline studies were performed within a few weeks after transplantation, as soon as the patient was stable enough to undergo cardiac catheterization; therefore, it is unlikely that significant vasculopathy developed in the postoperative period. Because there is a striking association between older donor age and the presence of coronary risk factors and the existence of intimal thickening on the predischarge examination by ultrasound, these data strongly suggest that the areas of focal intimal thickening observed in the baseline examination indeed represent transplanted preexistent disease.
The mechanism by which an older donor age predisposes to the subsequent
development of transplant coronary disease, as shown by
previous angiographic studies, is
unclear.6 7 11 12 This
study shows that, 2 years after transplantation, the degree of intimal
thickening in allografts with preexistent donor disease is higher than
in allografts without donor disease (Fig 5
). However,
progression of
the disease was not accelerated by the presence of donor disease (Fig
4
). Whether the data were analyzed per patient to provide more
meaningful information from a clinical point of view or per site to
provide more pathophysiological information on
the influence of focal donor disease, the results were not different.
Patients with preexistent donor disease have a higher degree of intimal
thickening 2 years after transplantation not because they progress more
but because they started at a higher level.
These data suggest that preexistent early native coronary artery lesions in the donor heart do not trigger the development of transplant vasculopathy. However, because sites with donor disease still are more heavily diseased 2 years after transplantation than sites without donor disease, the long-term clinical implications are uncertain. Interestingly, all patients with angiographically detectable coronary disease at the end of the follow-up had evidence of donor disease at the baseline examination as detected by intravascular ultrasound.
Study Limitations
This study concentrated only on the effect
of preexistent
coronary artery disease in the donor heart as a predictor of
progressive disease and did not analyze all the other factors
potentially affecting the process of vasculopathy in these patients.
Patients have not been treated differently at this institution on the
basis of the presence or absence of donor coronary artery
disease. These data were analyzed for each patient on the
assumption that clinical and laboratory factors in a given patient
might affect all lesions in the heart. Thus, data were averaged from
all sites for a given patient. However, the specific question of
whether sites with preexistent lesions progressed more rapidly led to
expression of the data for all sites as well. Although the sites may
not be data points independent of each other, the results seem the same
whether analyzed by patient or by site.
The potential limitation of correct location of the same site on serial studies of this type has been a concern of this research group and has been investigated. A rigorous procedure for duplication of angiographic projection, vessel segment studied, and imaging sites studied within the vessel was used in this study.15 34 Our reproducibility studies showed that, if the sites are not matched by ultrasound and angiography, the SD of the difference is approximately 12%. If the sites are well matched, the SD of the difference is only 6%. The matching process requires meticulous review of the reference ultrasound tapes and angiograms before the follow-up studies, followed by verification of the positions after the procedure. About 20% to 30% of the sites are discarded after this matching analysis. The difference in absolute measurements between the groups with or without preexisting donor disease in this study greatly exceeds the SD of the difference and therefore should not affect the conclusions drawn.
However, given that the progression in intimal
thickness is not
different between the two groups, ie, a negative finding, the power of
these analyses needs to be addressed. The power of these
analyses varies from 0.5 to 0.9, depending on the
parameters (MIT, II, or class) used. The group without
preexisting disease tends to progress even more at year 2 (Fig
4
).
Therefore, the conclusion that patients or sites with preexisting donor
disease do not progress more is probably valid. However, a larger
sample size (on the order of hundreds of patients) is needed to
validate this conclusion.35
The detection of early intimal
thickening and coronary
atheroma formation is limited by the resolution of the
imaging method used to enable visual appreciation of the process. Prior
studies suggested that the intracoronary ultrasonic imaging
system used in this study shows a pattern definable as intimal
thickening when the intima is >
178 µm thick.17 In
the current series, the visible lesions on the baseline studies did not
progress more than those areas without visible lesions. It is possible
that sites without baseline lesions actually progressed more than those
sites with visible donor disease, but we could not tell this because of
the resolution on the imaging system. Nevertheless, the conclusions
reached from the current data, namely that donor disease does not
predispose to more rapid progression of transplant vasculopathy, would
not be altered by that finding.
| Acknowledgments |
|---|
Received December 15, 1994; revision received March 2, 1995; accepted March 6, 1995.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. J. Shea, N. A Sopko, K. Ludrosky, K. Hoercher, N. G. Smedira, D. O. Taylor, R. C. Starling, and G. V. Gonzalez-Stawinski The effect of a donor's history of active substance on outcomes following orthotopic heart transplantation Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 452 - 456. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rahmani, R. P. Cruz, D. J. Granville, and B. M. McManus Allograft Vasculopathy Versus Atherosclerosis Circ. Res., October 13, 2006; 99(8): 801 - 815. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li, K. Tanaka, H. Anzai, B. Oeser, D. Lai, J. A. Kobashigawa, and J. M. Tobis Influence of Pre-Existing Donor Atherosclerosis on the Development of Cardiac Allograft Vasculopathy and Outcomes in Heart Transplant Recipients J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2470 - 2476. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Hauptman, K. J. O'Connor, R. E. Wolf, and B. J. McNeil Angiography of potential cardiac donors J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1252 - 1258. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. D. Knollmann, W. Bocksch, S. Spiegelsberger, R. Hetzer, R. Felix, and M. Hummel Electron-Beam Computed Tomography in the Assessment of Coronary Artery Disease After Heart Transplantation Circulation, May 2, 2000; 101(17): 2078 - 2082. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Rabago, A. Martin-Trenor, J.-L. Lopez Coronado, and J. Calabuig Coronary angioplasty and stenting following heart transplantation with older donors.: Is this a rational approach? Eur. J. Cardiothorac. Surg., February 1, 1998; 13(2): 209 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Weis and W. von Scheidt Cardiac Allograft Vasculopathy : A Review Circulation, September 16, 1997; 96(6): 2069 - 2077. [Abstract] [Full Text] |
||||
![]() |
P. J. Hauptman and K. J. O'Connor Procurement and Allocation of Solid Organs for Transplantation N. Engl. J. Med., February 6, 1997; 336(6): 422 - 431. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |